Somatostatin analogue - Italfarmaco

Drug Profile

Somatostatin analogue - Italfarmaco

Alternative Names: ITF-2984; ITF2984 diacetate

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Italfarmaco
  • Class Antihaemorrhagics; Antineoplastics; Cyclic peptides; Pancreatic hormones; Pituitary hormone release inhibiting hormones
  • Mechanism of Action Corticotropin-releasing-hormone-Inhibitors; Growth hormone releasing factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acromegaly
  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(In volunteers) in Italy (SC, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(In volunteers) in United Kingdom (SC, Injection)
  • 01 Feb 2016 Italfarmaco completes a phase II trial for Acromegaly in Czech Republic, France, Hungary, Italy, Netherlands, Poland, Romania, Serbia and Spain (NCT02111044)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top